6990 logo

Sichuan Kelun-Biotech Biopharmaceutical SHSC:6990 Stock Report

Last Price

HK$172.80

Market Cap

HK$38.5b

7D

5.9%

1Y

n/a

Updated

22 Jun, 2024

Data

Company Financials +

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SHSC:6990 Stock Report

Market Cap: HK$38.5b

6990 Stock Overview

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally.

6990 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sichuan Kelun-Biotech Biopharmaceutical
Historical stock prices
Current Share PriceHK$172.80
52 Week HighHK$195.00
52 Week LowHK$115.00
Beta0
11 Month Change-0.86%
3 Month Change5.49%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO46.81%

Recent News & Updates

Recent updates

Shareholder Returns

6990HK BiotechsHK Market
7D5.9%-2.5%0.6%
1Yn/a-33.0%2.4%

Return vs Industry: Insufficient data to determine how 6990 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 6990 performed against the Hong Kong Market.

Price Volatility

Is 6990's price volatile compared to industry and market?
6990 volatility
6990 Average Weekly Movement9.5%
Biotechs Industry Average Movement8.9%
Market Average Movement7.2%
10% most volatile stocks in HK Market15.3%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6990 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 6990's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20161,446Junyou Gekelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fundamentals Summary

How do Sichuan Kelun-Biotech Biopharmaceutical's earnings and revenue compare to its market cap?
6990 fundamental statistics
Market capHK$38.51b
Earnings (TTM)-HK$561.35m
Revenue (TTM)HK$1.66b

23.3x

P/S Ratio

-68.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6990 income statement (TTM)
RevenueCN¥1.54b
Cost of RevenueCN¥751.64m
Gross ProfitCN¥788.85m
Other ExpensesCN¥1.31b
Earnings-CN¥522.21m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.34
Gross Margin51.21%
Net Profit Margin-33.90%
Debt/Equity Ratio0%

How did 6990 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.